Non small cell lung cancer

非小细胞肺癌
  • 文章类型: Journal Article
    非小细胞肺癌(NSCLC)是最常见的肺癌类型,通常在晚期诊断(转移性)。转移性NSCLC的治疗选择包括放疗,化疗,目标药物治疗,和免疫疗法。免疫疗法(使用检查点抑制剂)可增强免疫系统以识别和破坏癌细胞。然而,它通常与免疫相关的并发症如肺炎有关.本文旨在确定接受不同免疫治疗药物治疗的转移性NSCLC患者肺炎的发生率。PubMed,科克伦图书馆,和Embase数据库进行随机对照试验(RCT),直至2023年10月.包含具有类似研究目标的已发表RCT,而非英语文章,reviews,病例报告,正在进行的试验,非随机研究,会议摘要,小细胞肺癌(SCLC)的研究被排除。使用Cochrane随机试验偏倚风险工具(RoB2)评估纳入研究的偏倚风险。采用综合Meta分析软件进行统计分析。对16个纳入RCT的亚组分析显示,接受纳武单抗和派博利珠单抗治疗的转移性NSCLC患者的任何级别肺炎发生率均高于接受阿特珠单抗治疗的患者(4.5%和5.1%vs.1.6%,分别)。同样,接受纳武单抗(1.3%)和派博利珠单抗(2.4%)的患者的≥3级肺炎发生率高于接受阿特珠单抗(0.7%).此外,亚组分析显示,接受免疫治疗的初次治疗的NSCLC患者的任何级别肺炎发生率均高于先前治疗的NSCLC患者(6.5%vs.3.9%)。未接受治疗的患者记录的≥3级肺炎发生率高于先前接受治疗的患者(3.1%vs.1.3%)。程序性死亡1(PD-1)抑制剂(即,pembrolizumab和nivolumab)的肺炎发生率高于程序性死亡配体1抑制剂(阿特珠单抗)。
    Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, often diagnosed at the advanced stage (metastatic). Treatment options for metastatic NSCLC include radiotherapy, chemotherapy, target drug therapy, and immunotherapy. Immunotherapy (utilization of checkpoint inhibitors) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. This review aims to determine the incidence of pneumonitis in metastatic NSCLC patients treated with different immunotherapy drugs. PubMed, Cochrane Library, and Embase databases were scoured for randomized controlled trials (RCTs) until October 2023. Published RCTs with similar research objectives were included, while non-English articles, reviews, case reports, ongoing trials, non-randomized studies, conference abstracts, and studies on small cell lung cancer (SCLC) were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB 2) was used to assess the risk of bias among the included studies. The statistical analyses were performed with the Comprehensive Meta-Analysis software. The subgroup analysis of the 16 included RCTs showed that metastatic NSCLC patients treated with nivolumab and pembrolizumab had a higher incidence of any grade pneumonitis than those treated with atezolizumab (4.5% and 5.1% vs. 1.6%, respectively). Similarly, the incidence of grade ≥3 pneumonitis was higher among patients receiving nivolumab (1.3%) and pembrolizumab (2.4%) than those receiving atezolizumab (0.7%). Furthermore, the subgroup analysis showed that patients with naive-treated NSCLC on immunotherapy had a higher incidence of any grade pneumonitis than those with previously treated NSCLC (6.5% vs. 3.9%). Treatment-naive patients recorded higher grade ≥3 pneumonitis incidences than those previously treated (3.1% vs. 1.3%). Programmed death 1 (PD-1) inhibitors (i.e., pembrolizumab and nivolumab) have higher incidences of pneumonitis than programmed death-ligand 1 inhibitors (atezolizumab).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:确定特定的生物标志物将有助于非小细胞肺癌(NSCLC)的诊断和预测。本研究旨在探讨非小细胞肺癌患者和健康志愿者血清SH2B1水平,建立新的预测模型。
    方法:选择2019年12月至2020年12月的NSCLC患者103例和健康志愿者108例。收集他们的血清和重要临床资料。通过ELISA测定血清SH2B1浓度。根据这些重要因素,建立了一种新的NSCLC预测模型。
    结果:多因素logistic回归分析显示,慢性肺病患者NLR≥2.07,血红蛋白水平≥136.56g/L,白蛋白水平≥42.59g/L,血清SH2B1浓度≥615.28pg/mL差异有统计学意义(p<0.05)。基于血清SH2B1浓度结合重要临床指标建立综合列线图以预测个体NSCLC的概率。
    结论:血清SH2B1浓度≥615.28pg/mL是NSCLC的重要预测因素。重要的是,基于血清SH2B1的预测模型具有良好的稳定性和准确性,这为NSCLC的预测评估提供了新的见解。
    BACKGROUND: Identifying a specific biomarker will facilitate the diagnosis and prediction of non-small cell lung cancer (NSCLC). The aim of this study was to investigate the serum SH2B1 in patients with NSCLC and healthy volunteers and establish a novel prediction model.
    METHODS: A total 103 NSCLC patients and 108 healthy volunteers were selected from December 2019 to December 2020. Their serum and important clinical data were collected. Serum SH2B1 concentration was determined by ELISA. A novel prediction model for NSCLC was established according to these significant factors.
    RESULTS: Multivariate logistic regression analysis indicated that the chronic pulmonary diseases; NLR ≥ 2.07; hemoglobin level ≥ 136.56 g/L; albumin level ≥ 42.59 g/L and serum SH2B1 concentration ≥615.28 pg/mL were considered as statistically significant difference (p < 0.05). A comprehensive nomogram was established based on serum SH2B1 concentration combined with significant clinical indicators to predict an individual\'s probability of NSCLC.
    CONCLUSIONS: The serum SH2B1 concentration ≥ 615.28 pg/mL is a significant predictive factor for NSCLC. Significantly, the prediction model based on serum SH2B1 has good stability and accuracy, which provides new insights of prediction assessment for NSCLC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:《平价医疗法案》扩大了美国低收入人群的医疗补助覆盖范围。扩大保险范围可以促进更及时地获得癌症治疗,这可以提高总生存率(OS),然而,医疗补助扩大(ME)的长期影响仍然未知。我们评估了乳腺癌患者的ME是否与改善的及时治疗开始(TTI)和3年OS相关,子宫颈,结肠,和受政策影响的肺癌。
    方法:医疗补助保险或未保险的患者,年龄在40-64岁,患有I-III期乳房,子宫颈,结肠,或国家癌症数据库(NCDB)中的非小细胞肺癌。使用差异差异(DID)方法比较ME状态患者与非扩张(NE)状态患者之间TTI(60天内)和3年OS的变化(2010-2013年)和(2015-2018年)ME之前。使用多变量线性回归和Cox比例风险回归模型计算TTI和3年OS的调整后DID估计值,分别。
    结果:ME与60天内乳腺TTI的相对增加相关(DID=4.6;p<0.001),宫颈(DID=5.0p=0.013),和冒号(DID=4.0,p=0.008),但不是肺癌(p=0.505)。在Cox回归分析中,ME与改善乳房的3年OS相关(DID危险比[HR]=0.82,p=0.009),宫颈(DID-HR=0.81,p=0.048),和肺(DID-HR=0.87,p=0.003)。结肠癌的3年OS变化在ME和NE状态之间没有统计学差异(DID-HR,0.77;p=0.075)。
    结论:研究结果表明,扩大保险范围可以改善低收入和无保险癌症患者的治疗和生存结果。随着围绕我的辩论在全国范围内继续,我们的研究结果为制定旨在促进人人享有和负担得起的医疗保健的政策提供了宝贵的见解。
    BACKGROUND: The Affordable Care Act expanded Medicaid coverage for people with low income in the United States. Expanded insurance coverage could promote more timely access to cancer treatment, which could improve overall survival (OS), yet the long-term effects of Medicaid expansion (ME) remain unknown. We evaluated whether ME was associated with improved timely treatment initiation (TTI) and 3-year OS among patients with breast, cervical, colon, and lung cancers who were affected by the policy.
    METHODS: Medicaid-insured or uninsured patients aged 40-64 with stage I-III breast, cervical, colon, or non-small cell lung cancer within the National Cancer Database (NCDB). A difference-in-differences (DID) approach was used to compare changes in TTI (within 60 days) and 3-year OS between patients in ME states versus nonexpansion (NE) states before (2010-2013) and after (2015-2018) ME. Adjusted DID estimates for TTI and 3-year OS were calculated using multivariable linear regression and Cox proportional hazards regression models, respectively.
    RESULTS: ME was associated with a relative increase in TTI within 60 days for breast (DID = 4.6; p < 0.001), cervical (DID = 5.0 p = 0.013), and colon (DID = 4.0, p = 0.008), but not lung cancer (p = 0.505). In Cox regression analysis, ME was associated with improved 3-year OS for breast (DID hazard ratio [HR] = 0.82, p = 0.009), cervical (DID-HR = 0.81, p = 0.048), and lung (DID-HR = 0.87, p = 0.003). Changes in 3-year OS for colon cancer were not statistically different between ME and NE states (DID-HR, 0.77; p = 0.075).
    CONCLUSIONS: Findings suggest that expanded insurance coverage can improve treatment and survival outcomes among low income and uninsured patients with cancer. As the debate surrounding ME continues nationwide, our findings serve as valuable insights to inform the development of policies aimed at fostering accessible and affordable healthcare for all.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:肺癌是全球癌症相关死亡率的最常见原因之一。通过支持肿瘤生长,血小板已成为癌症发展和进展的关键参与者,和传播。在本系统综述中,我们分析了癌细胞和血小板之间的RNA转移,并探讨了不同血小板RNA谱在诊断中的潜在作用,亚型,肺癌的疾病进展和治疗监测。
    方法:该研究遵循了系统评价和Meta分析指南的首选报告项目和Cochrane系统评价和Meta分析手册,其中包括七项关于肺癌患者的研究,有肿瘤检测血小板的数据,和对照组。测量的结果是基于敏感性,特异性,ROC。pubmed,Scopus,在2023年10月之前,使用特定的搜索词搜索了Cochrane中央对照试验登记处和ScienceDirect数据库。QUADAS-2工具用于评估质量,偏差风险和适用性问题。
    结果:分析显示不同血小板mRNA的AUC>70%,敏感性和特异性超过60%。ITGA2B的AUC和灵敏度最高(AUC0.922;灵敏度92.8%)。lncRNAGTF2H2-1是最特异的血小板RNA。在QUADAS-2工具上,3/7文章在参考标准中不清楚,患者流量计时,1/7在这两个方面都有较高的偏倚。为了适用性,1/7的研究在参考标准中不清楚,和2/7指数测试。
    结论:TEPRNA可以帮助肺癌的早期诊断,并在其早期检测中得到证实。TEPRNA还可以监测疾病进展和治疗反应。
    BACKGROUND: Lung cancer is one of the commonest cause of cancer associated mortality worldwide. Platelets have emerged as key players in cancer development and progression by supporting tumor growth, and dissemination. In the present systematic review, we analyzed RNA transfer between cancer cells and platelets and explored potential role of different platelet RNA profiles as onco-signature in diagnosis, subtyping, disease progression and treatment monitoring in carcinoma lung carcinoma.
    METHODS: The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and Cochrane Manual of Systematic Reviews and Meta-analysis that included seven studies on patients with lung cancer, with data on tumor-educated platelets, and control group. The outcome measured was based on sensitivity, specificity, and ROC. PUBMED, SCOPUS, Central Cochrane Registry of Controlled Trials and Science Direct databases were searched using specific search terms until October 2023. QUADAS - 2 tool was used to assess quality, risk of bias and applicability concerns.
    RESULTS: The analysis revealed AUC > 70% for different platelet mRNAs, with sensitivity and specificity of more than 60 %. AUC and sensitivity were highest for ITGA2B (AUC 0.922; sensitivity 92.8%). lncRNA GTF2H2-1 was the most specific platelet RNA. On QUADAS-2 tool, 3/7 articles were unclear in reference standards, patient flow timing, and 1/7 had high bias in both aspects. For applicability, 1/7 studies were unclear in reference standards, and 2/7 in index tests.
    CONCLUSIONS: TEP RNA can aid in early diagnosis of lung cancer and of proven utility in its early-stage detection. TEP RNA can also monitor disease progression and treatment response.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:肺癌是全球癌症死亡的主要原因,诊断仍然具有挑战性。肺癌从小结节开始,早期准确诊断,可以及时手术切除恶性结节,同时避免良性结节患者不必要的手术。
    目的:Cole弛豫频率(CRF)是衍生的电生物阻抗特征,其可用于区分癌组织与正常组织。
    方法:用NoduleScan在30例接受非小细胞肺癌切除术的志愿者患者新鲜切除的肺组织中进行离体人体测试。将肿瘤的CRF和相对于肿瘤的远处正常肺组织与组织病理学标本进行比较,以建立潜在的即时诊断算法。用于体内动物试验,用皮下注射到每只小鼠右侧腹中的异种移植人肺癌肿瘤细胞植入20只小鼠。对活体动物上的肿瘤和安乐死后的肿瘤进行光谱阻抗测量。将这些CRF测量值与健康小鼠肺组织进行比较。对于离体猪肺测试,猪肺与气管一起接受。拆除声箱后,连接呼吸机以对肺加压并模拟呼吸.在裂片的不同位置,肺的表面被切割,以产生一个口袋,可以容纳从体内动物试验获得的肿瘤。肿瘤被放置在肺的表面下,并且将电极放置在肿瘤正上方的肺表面上,但在肿瘤和电极之间有肺组织。频谱阻抗测量是在肺部处于放气状态时进行的,充气状态,以及在通货膨胀-通货紧缩过程中模拟呼吸。
    结果:在30例患者中评估的60个样本中,NoduleScan允许在肿瘤和远处正常组织中CRF清晰分离的患者中以高度的敏感性(97%)和特异性(87%)进行现成的区分。在25个异种移植小动物模型标本中测得,CRF与人体内测量中观察到的分离对齐。CRF成功测量了植入离体猪肺的肿瘤,和CRF测量值与以前的加压和非加压肺测试一致。
    结论:如先前在乳腺组织中所示,在1kHz-10MHz范围内的CRF能够区分非小细胞肺癌和正常组织。Further,体内小动物研究证明了这一点,灌注肿瘤具有与乳腺组织和人离体测试中所示相同的CRF特征。肺的膨胀和收缩对CRF特征没有影响。随着额外的发展,从频谱阻抗测量得出的CRF可以允许指导手术切除的现场护理诊断。
    BACKGROUND: Lung cancer is the world\'s leading cause of cancer deaths, and diagnosis remains challenging. Lung cancer starts as small nodules; early and accurate diagnosis allows timely surgical resection of malignant nodules while avoiding unnecessary surgery in patients with benign nodules.
    OBJECTIVE: The Cole relaxation frequency (CRF) is a derived electrical bioimpedance signature, which may be utilized to distinguish cancerous tissues from normal tissues.
    METHODS: Human testing ex vivo was conducted with NoduleScan in freshly resected lung tissue from 30 volunteer patients undergoing resection for nonsmall cell lung cancer. The CRF of the tumor and the distant normal lung tissue relative to the tumor were compared to histopathology specimens to establish a potential algorithm for point-of-care diagnosis. For animal testing in vivo, 20 mice were implanted with xenograft human lung cancer tumor cells injected subcutaneously into the right flank of each mouse. Spectral impedance measurements were taken on the tumors on live animals transcutaneously and on the tumors after euthanasia. These CRF measurements were compared to healthy mouse lung tissue. For porcine lung testing ex vivo, porcine lungs were received with the trachea. After removal of the vocal box, a ventilator was attached to pressurize the lung and simulate breathing. At different locations of the lobes, the lung\'s surface was cut to produce a pocket that could accommodate tumors obtained from in vivo animal testing. The tumors were placed in the subsurface of the lung, and the electrode was placed on top of the lung surface directly over the tumor but with lung tissue between the tumor and the electrode. Spectral impedance measurements were taken when the lungs were in the deflated state, inflated state, and also during the inflation-deflation process to simulate breathing.
    RESULTS: Among 60 specimens evaluated in 30 patients, NoduleScan allowed ready discrimination in patients with clear separation of CRF in tumor and distant normal tissue with a high degree of sensitivity (97%) and specificity (87%). In the 25 xenograft small animal model specimens measured, the CRF aligns with the separation observed in the human in vivo measurements. The CRF was successfully measured of tumors implanted into ex vivo porcine lungs, and CRF measurements aligned with previous tests for pressurized and unpressurized lungs.
    CONCLUSIONS: As previously shown in breast tissue, CRF in the range of 1kHz-10MHz was able to distinguish nonsmall cell lung cancer versus normal tissue. Further, as evidenced by in vivo small animal studies, perfused tumors have the same CRF signature as shown in breast tissue and human ex vivo testing. Inflation and deflation of the lung have no effect on the CRF signature. With additional development, CRF derived from spectral impedance measurements may permit point-of-care diagnosis guiding surgical resection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    Sweet综合征是一种罕见的炎症性疾病,其特征是突然出现疼痛,红斑丘疹,斑块,或者皮肤上的结节.发热和白细胞增多常伴随皮肤病变。此外,眼睛的参与,肌肉骨骼系统,和内部器官可能发生。Sweet综合征与广泛的疾病有关。有三种亚型:经典的Sweet综合征,恶性肿瘤相关的Sweet综合征,和药物诱发的Sweet综合征.经典的Sweet综合征与恶性肿瘤或药物无关。它基本上与上呼吸道感染有关,胃肠道感染,炎症性肠病,和怀孕。恶性相关的Sweet综合征与血液系统恶性肿瘤的相关性大于实体恶性肿瘤,最常见的是急性髓细胞性白血病。药物诱发的Sweet综合征通常在药物暴露后大约两周出现,在没有接触过煽动性药物史的患者中。我们在讨论我们的病人,一名68岁男性在开始培美曲塞化疗8周后出现,卡铂,和派博利珠单抗治疗左肺腺癌伴黄斑皮疹。经进一步活检发现有嗜中性粒细胞性皮炎,因此被诊断为药物诱导的Sweet综合征。组织病理学显示真皮有嗜中性粒细胞浸润并伴有红细胞增多症。
    Sweet syndrome is an uncommon inflammatory disorder characterized by the abrupt appearance of painful, erythematous papules, plaques, or nodules on the skin. Fever and leukocytosis frequently accompany the cutaneous lesions. In addition, involvement of the eyes, musculoskeletal system, and internal organs may occur. Sweet syndrome has been associated with a broad range of disorders. There are three subtypes: classical Sweet syndrome, malignancy-associated Sweet syndrome, and drug-induced Sweet syndrome. Classical Sweet syndrome is not associated with malignancy or drugs. It is essentially associated with an upper respiratory infection, gastrointestinal infection, inflammatory bowel disease, and pregnancy. Malignancy-associated Sweet syndrome is associated with hematologic malignancy more than solid malignancy, most commonly with acute myeloid leukemia. Drug-induced Sweet syndrome usually develops approximately two weeks after drug exposure, in patients who lack a prior history of exposure to the inciting drug. Here we are discussing our patient, a 68-year-old male who presented eight weeks after starting chemotherapy with pemetrexed, carboplatin, and pembrolizumab for left lung adenocarcinoma with macular rash. On further investigation with biopsy was found to have neutrophilic dermatitis, hence being diagnosed with drug-induced Sweet syndrome. Histopathology revealed a dermis with infiltration of neutrophils with lekocytoclasia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    非小细胞肺癌转移到骨骼肌是一种罕见的现象。肺癌更有可能扩散到大脑,骨头,肝脏,和肾上腺。这里,我们介绍了一例54岁男性的非小细胞肺癌转移至骨骼肌的罕见病例。此外,本文对非小细胞肺癌的骨转移进行了文献综述。骨骼肌转移最常见的表现是伴有或不伴有肿胀的肌肉疼痛。向肌肉转移的机制尚不清楚;从理论上讲,血行扩散是最可能的途径。和我们的病人一样,骨骼肌质量的存在被认为是一种生存不良的侵袭性疾病,通常不到一年。肌肉转移的治疗通常以放射治疗的形式姑息,化疗,或手术切除肿块。
    Non-small cell lung cancer metastasis to skeletal muscle is an uncommon occurrence. Lung cancers are more likely to spread to the brain, bone, liver, and adrenals. Here, we present a rare case of non-small cell lung cancer metastasis to the skeletal muscle in a 54-year-old male. In addition, we present a literature review on skeletal metastasis of non-small cell lung cancer. The most frequent presentation of skeletal muscle metastasis is muscular pain with or without swelling. The mechanism of metastasis to muscle is not well understood; it is theorized that hematogenous spread is the most likely route. As with our patient, the presence of skeletal muscle mass is considered an aggressive disease with poor survival, usually less than one year. The treatment for muscle metastasis is often palliative in the form of radiation therapy, chemotherapy, or surgical removal of the mass.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    肺癌是与副肿瘤综合征相关的最常见的肿瘤性疾病。最常见的副肿瘤综合征是抗利尿激素(SIADH)不适当释放综合征,恶性肿瘤的高钙血症,异位库欣综合征,和其他各种神经综合征。一些病例报告报道了妇科乳房发育为副肿瘤综合征。识别这种罕见的表现可以帮助早期发现相关的恶性肿瘤,从而有可能改善结果。在这篇文章中,我们正在介绍一个60多岁的男性患者的案例,在介绍时,患有男性乳房发育症,最终被诊断为非小细胞肺癌(NSCLC)。
    Lung cancer is the most common neoplastic disorder associated with paraneoplastic syndromes. The most common paraneoplastic syndromes are the syndrome of inappropriate release of antidiuretic hormone (SIADH), hypercalcemia of malignancy, ectopic Cushing\'s syndrome, and various other neurological syndromes. A few case reports have reported gynecomastia as a paraneoplastic syndrome. Recognition of this uncommon presentation can aid in the early detection of associated malignancies, thus potentially improving outcomes. In this article, we are presenting the case of a male patient in his late sixties who, on presentation, had gynecomastia and was eventually diagnosed with non-small-cell lung cancer (NSCLC).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    肺肉瘤样癌(SC)是一类异质性散发性的非小细胞肺癌(NSCLCs),诊断和治疗具有挑战性。梭形细胞癌(SpCC)是该组中非常罕见的子集。因此,由于文献有限,预后和治疗尚不清楚.这种癌症的表现根据肿瘤的部位以及诊断时观察到的并发症和转移而变化。这里,我们报道了一名73岁的男性,他在呼吸困难和疲劳恶化两个月后到急诊室就诊.胸部X线显示广泛的左侧胸腔积液。胸部计算机断层扫描(CT)扫描显示胸膜肿块,返回为SpCC,为此他被转诊到一所大学医院。
    The lung\'s sarcomatoid carcinomas (SC) are a heterogeneous sporadic group of non-small cell lung carcinomas (NSCLCs) and are very challenging to diagnose and treat. Spindle cell carcinoma (SpCC) is a very rare subset of this group. Hence, the prognosis and treatments are unclear due to the limited literature available. The presentation of this cancer varies based on the site of the neoplasm and the complications and metastases observed at the time of diagnosis. Here, we report a 73-year-old man who presented to the emergency room after two months of worsening dyspnea and fatigue. Chest X-ray showed an extensive left-sided pleural effusion. A computed tomography (CT) scan of the chest showed a pleural-based mass that came back as SpCC, for which he was referred to a university hospital.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    肺腺癌,非小细胞肺癌的主要亚型,通常转移到肝脏和肾上腺等常见部位。然而,罕见病例涉及骨骼肌转移。我们介绍了一个45岁的女性,有高血压病史,癫痫,和纤维肌痛,他因咯血和多灶性疼痛到急诊科就诊。胸部成像显示空洞性病变,似乎是坏死性肺炎。进一步的调查发现左大腿有液体聚集,这将被确定为低分化癌。随后的测试将肺确定为转移的主要来源。尽管进行了放射治疗,病人的病情在接下来的50天内恶化,突出了疾病的侵袭性。
    Lung adenocarcinoma, the predominant subtype of non-small cell lung cancer, typically metastasizes to common sites such as the liver and adrenal glands. However, rare instances involve skeletal muscle metastasis. We present a case of a 45-year-old female with a medical history of hypertension, epilepsy, and fibromyalgia, who presented to the emergency department with hemoptysis and multifocal pain. Chest imaging revealed a cavitary lesion which appeared to be necrotizing pneumonia. Further investigations uncovered a fluid collection in the left thigh, which would be identified as poorly differentiated carcinoma. Subsequent testing identified the lung as the primary source of metastasis. Despite radiation treatment, the patient\'s condition deteriorated over the next 50 days, highlighting the aggressive nature of the disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号